

OPEN SOURCE IMAGING CONSORTIUM

against Interstitial Lung Disease

Quantitative Imaging Workshop

NOVEMBER 2, 2023

Dr. Simon Walsh - Imperial College, London Elizabeth Estes - OSIC

OSIC Mission

Be passionate in our quest to make **radical** progress on behalf of people living with fibrosing lung diseases, their families and caregivers.

Drive ecosystem innovation and efficiencies to deliver <u>actionable</u> solutions to clinicians.


- Not-for-profit, co-operative effort between academia, industry and philanthropy – founded in 2017
 - Academic institutions provide minimum 500 scans to receive access to entire database and consortium
 - Industry and Technology Partners fee based
 - Patient organizations are free
- The largest and most diverse, curated and integrated ILD image and clinical database
- Accessible machine learning, imaging and pulmonology expertise
- Speed of progression achieved with the open science model



Imaging Is Vital for Clinical Progress in ILD

Imaging vs. FVC

- FVC (the current SOC) is a bad endpoint/metric of disease severity
 - Mechanistically uninformative
 - Lags behind changes in the lungs
- Imaging can be a less variable biomarker for disease progression and can allow quantification
- Imaging can play a major role in drug trial eligibility
 - Reducing drug trial cost and failed trials
 - Reducing chances of companies giving up
- Reduce lung biopsies and other unnecessary tests which burden the system and worse – cause patients distress
- Today's tools can find patterns and with expertise, make meaning from the patterns
- Today's tools can see things the human eye can't



Almost 50% of screen failures in IPF drug trials are from misclassification of HRCT at central read

ILD Real World Diagnostic Challenge #1

Experts Often Cannot Agree

AMERICAN THORACIC SOCIETY DOCUMENTS

Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Ganesh Raghu, Martine Remy-Jardin, Jeffrey L. Myers, Luca Richeldi, Christopher J. Ryerson, David J. Lederer, Juergen Behr, Vincent Cottin, Sonye K. Danoff, Ferran Morell, Kevin R. Flaherty, Athol Wells, Fernando J. Martinez, Arata Azuma, Thomas J. Bice, Demosthenes Bouros, Kevin K. Brown, Harold R. Collard, Abhijit Duggal, Liam Galvin, Yoshikazu Inoue, R. Gisli Jenkins, Takeshi Johkoh, Ella A. Kazerconi, Masanori Kitaichi, Shandra L. Knight, George Mansour, Andrew G. Nicholson, Sudhakar N. J. Pipavath, Ivette Buendia-Roldán, Moisés Selman, William D. Travis, Simon L. F. Walsh, and Kevin C. Wilson; on behalf of the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society

THE ORIGIN, CURCIN, PRINCING SUDELING OF THE AMERICAN THORAGO SOCIETY (ATS), EXPOREM RESERVORY SOCIETY (ERS), JURYASSE RESERVORY SOCIETY (JRS), AND LATIN AMERICAN THORAGO SOCIETY (ALAT) WAS APPRICED BY THE ATS, JRS, MIC ALAT MAY 2015, AND THE ERS JUNE 2015

Subpleural and basal	Subpleural and basal	Subpleural and basal predominant	Findings suggestive of another		
predominant; distribution is often heterogeneous'	predominant; distribution is often heterogeneous	Subtle reticulation; may have mild GGO or distortion ("early UP pattern")	 diagnosis, including: CT features; Oysts 		
Honeycombing with or without perpheral traction bronchiectasis or	Reticular pattern with peripheral traction bronchiectasis or bronchielectasis	CT features and/or distribution of lung fibrosis that do not suggest	Marked mosaic attenuation Predominant GGO		
bronchiolectasis [†]	May have mild GGO	any specific etiology ("truly indeterminate for UIP")	 Profuse micronodules Centrilobular nodules Nodules Consolidation 		
			 Predominant distribution: Peribronchovascular Penlymphatic Upper or mid-lung 		
			Other: Pleural plaques (conside asbestosis) Diatod osophagus (consider GTD) Distal clavicular enolen (consider FA) Extensive (yright node enargement (consider other etiologies) Pleural refutions, pleura thickening (consider CTD4/uco)		



Probable UIP







THE LANCET **Respiratory Medicine**

Deep learning for classifying fibrotic lung disease on high-resolution computed tomography: a case-cohort study





Lancet Respir Med 2018

Summary

Background Based on international diagnostic guidelines, high-resolution CT plays a central part in the diagnosis of

the correct clinical context, when high-resolution CT appearances are those of usual interstitial s of idiopathic pulmonary fibrosis can be made without surgical lung biopsy. We investigated ning algorithm for provision of automated classification of fibrotic lung disease on high-3 to criteria specified in two international diagnostic guideline statements: the 2011 American //European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American ALAT) guidelines for diagnosis and management of idiopathic pulmonary fibrosis and the 10stic criteria for idiopathic pulmonary fibrosis.

Department of Radiology, King's College Hospital Foundation Trust, London, UK (SLF Walsh MD); Department of Radiology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy (I. Calandriello MD); and Department of Medicine and Surgery, University of Parma, Parma, Italy-(M Silva MD, Prof N Sverzellati PhD)











OSIC - Solving ILD Real World Diagnostic Problem #1

Experts Often Can't Agree

- Prior Limitations
 - Insufficient number of CT scans available
 - Databases were primarily homogeneous
 - Limited collaborations
 - Generative AI needs lots of data

OSIC Approach

- Build the largest, most diverse and curated real-world dataset
 - From every region in the world
- Cloud-enabled data handling and distribution
 - New OSIC Cloud launching November 13th
- Help remove variability from image analysis
- Search for novel biomarkers

Current repository overview **20,752** Total committed datasets 4,924 anonymized patients **6,322** anonymized scans

Learnings

- Images alone are not enough. Curated datasets are vital for algorithm development
- Real world data is important vs. pristine only
- The front-end ecosystem needs more standards
 - Radiology
 - EMR
- Pulmonologists need to be at forefront of understanding the input needs of the tools

ILD Real World Diagnostic Challenge #2


Identifying Progressive Disease

Once disease is established

It is currently not possible to reliably predict which patients will develop progressive fibrosis or remain stable using BASELINE information.



Stable disease



SOFIA-based prob	oabi	lities
------------------	------	--------

UIP:	0.9963
PROB:	0.0036
INDETER:	0.0001
OTHER:	0.0000

- Precious time wasted (more than 1 year)
- More lung biopsies (2%, 30-day mortality)
- Patient exposure to harmful medications
- Increased healthcare costs



Progressive fibrotic phenotype

OSIC - Solving ILD Real World Diagnostic Problem #2

Identifying Progressive Disease

OSIC Approach


- Ongoing refinement of clinical data needed for best algorithm output
 - Share, test, debate.....repeat
- Drive collection of longitudinal scans and data
- Artificial intelligence models for quantification of progression

Path Forward

- Begin more annotation of data
- Add other forms of data
 - Sound
 - Blood biomarkers
 - Clinical notes NLP
 - Project OPUS
- Test member algorithms against a similar cohort

d for best

Lung Quantification in ILD



LungQ[™] AVX

ILA quantification







extflow ADVANC	E Chest CT - Image Ana	lysis Results
		ALCONTROL .
hneoXVpd7pKUPh	-1K4TFA-	
Michael SCOTT		
ste: 01/01/1961	Seic M	
description.		
its: 30/11/1899	Size Thickness 1	Reconstruction Karnel: YB

Nodule Detection Results Detected redules: 9 - see section Lung Nodule Detection for a detailed report

Ing	Tissue Analysis	Results

Pattern	Lung	2	LeftL	ne -	Rights	ung .
Tetal Lung Volume	100 %	5.8 L	48 %	2.8L	52.%	3.01
Meural Cavity	0%	8.0%	11%	8.01	61%	0.01
Effusion	<1%	8.0%	455	0.04	.+1%	0.01
 Pneumothoras 	<1%	0.01	+ 5.%	9.01	+1%	0.01
Lung Parenchyma	100 %	5.81	48.%	2.81	52%	3.01
 Consolidation 	<1%	0.0%	<1%	0.01	+1%	0.01
Emphysema	<1%	0.01,	36.%	0.01	64%	0.01
Ground-glass opacity	1%	0.11	50 N.	0.0 L	50 %	0.01
Honeycombing	<1.76	2.01	<1%	0.01	+2%	0.01
Reticular pattern	1%	0.11	37.%	0.01	63%	0.01
Other	3%	0.21	57 %	0.11	43%	0.11
Unremarkable	95%	5.51	48.%	2.61	52%	2.91

€€ 0123	Product name: contextRee ADMANCE Chest CT Product version: 2.2.0 UDI: 09120307330099	-	Manufacturer contextflave GmbH contextflave GmbH, Margarekenstrasse 70/218, 2050 Venna, AU\$TRA were contextflave com	
---------	---	---	--	--


ILD Real World Diagnostic Challenge #3

Early detection of progressive fibrosing lung disease – symptom based diagnosis

ILA's 7-9 per 100

IPR: 1-63 per 100,000

- Symptom Based Diagnosis
 - Symptoms alert clinician
 - Established fibrosis on HRCT
 - Early intervention "opportunity" missed
 - Irrevocable lung function loss
- "It's like diagnosing coronary artery disease after someone had a heart attack"



OSIC - Solving ILD Real World Diagnostic Problem #3

Early detection of ILD – symptom based

OSIC Approach

- Including lung cancer screening data into our cloud database for the purpose of ILA and ILD
- Categorize the abnormalities and create algorithmic based biomarkers for ILA's and progressive ILD's

Path Forward


- 10,000 Lung cancer screenings to be added by end of 2023 with ILA and ILD follow ups
- Goal is 100,000 in 2024 with 40,000 committed





Something To Think About

The Data Scarcity Problem in Rare Disease – The Need for Generative AI and Synthetic Data



0

Thank you for inviting us to be here.

eestes@osicild.org www.osicild.org